DGAP-News: Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the

DGAP-News: Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic 
Idiopathic Constipation at Annual Meeting of the Swiss Society of 
Gastroenterology

Sucampo Pharmaceuticals, Inc. 

13.09.2013 01:00
---------------------------------------------------------------------------

BETHESDA, Md., 2013-09-13 01:00 CEST (GLOBE NEWSWIRE) --
Sucampo AG ('SAG'), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc.
(Nasdaq:SCMP) ('Sucampo'), announced today that it will present four posters
evaluating the overall efficacy and tolerability of AMITIZA(r) (lubiprostone) as
a treatment for chronic idiopathic constipation (CIC). These posters contain
data demonstrating the efficacy and tolerability of AMITIZA regardless of age,
gender, and race, a pooled analysis of the most frequent adverse events
associated with AMITIZA, and an evaluation of the efficacy of AMITIZA in
patients suffering from refractory constipation. Sucampo will present these
data during the Annual Meeting of the Swiss Society of Gastroenterology in
Basel, Switzerland on Friday, September 13, 2013. 

'AMITIZA has been proven to be effective in treating a wide range of patients
suffering from CIC,' said Ryuji Ueno, MD, PhD, PhD, SAG's President and Chief
Scientific Officer. 'We are excited to present these data on AMITIZA, the
world's first chloride channel activator, to gastroenterologists in
Switzerland.' 

AMITIZA increases intestinal fluid secretion, softens stools and increases
motility in the intestine, thereby facilitating the passage of stool and
alleviating symptoms associated with CIC. 

The following posters will be presented between 1:30-2:00 p.m. CEST (7:30-8:00
a.m. ET) at the Annual Meeting of the Swiss Society of Gastroenterology at the
Basel Congress Center in Basel, Switzerland on Friday, September 13, 2013: 

  -- Long-Term Efficacy of Lubiprostone Demonstrated in Patients with
     Constipation Regardless of Age, Gender or Race

  -- Taryn R. Joswick, BS, PMP, Gayle R. Dolecek, PD, MPH, Peter Lichtlen MD,
     PhD, Ryuji Ueno, MD, PhD, PhD, Poster G9

  -- Lubiprostone Treatment Improves Constipation and Related Symptoms in
     Patients Refractory to Other Constipation Therapies

  -- Taryn R. Joswick, BS, PMP, Raymond M. Panas, PhD, Peter Lichtlen MD, PhD,
     Ryuji Ueno, MD, PhD, PhD, Poster G10

  -- Lubiprostone Demonstrates Efficacy in Adult Patients with Constipation
     Regardless of Age, Gender or Race

  -- Taryn Joswick, BS, PMP, Gayle R. Dolecek, PD, MPH, Raymond M. Panas PhD,
     Ryuji Ueno, MD, PhD, PhD, Poster G11

  -- Pooled Analysis of the Most Frequent Adverse Events Associated with the Use
     of Lubiprostone

  -- Taryn R. Joswick, BS, PMP, Gayle R. Dolecek, PD, MPH, Ryuji Ueno, MD, PhD,
     PhD, Poster G12

Sucampo will also be present in the exhibition hall with a booth located at E38.

Additional information about the Annual Meeting of the Swiss Society of
Gastroenterology can be found at http://www.sgg-sgvc-congress.ch/. 

About AMITIZA

AMITIZA (lubiprostone) capsules are indicated in Switzerland for the treatment
of chronic idiopathic constipation (CIC) in adults aged 18 and above. Sucampo
began active commercialization of AMITIZA in Switzerland for CIC in the second
quarter of 2013. 

Short Prescribing Information (Switzerland)

Before prescribing AMITIZA please consult the full Prescribing Information
(www.swissmedicinfo.ch). Composition: Soft capsule, 24 ug lubiprostone.
Indication: treatment of chronic idiopathic constipation in adults aged 18 and
above. Dosage: One 24 ug capsule should be taken twice daily with food. The
need for continued therapy must be assessed at regular intervals by stopping
treatment. Contraindication: must not be used for patients with a medical
history of known or suspected mechanical gastrointestinal obstructions or with
known oversensitivity to the active ingredient or one of the excipients.
Precaution: Patients may experience nausea. If this occurs, concomitant
administration of food may reduce symptoms. AMITIZA should not be prescribed to
patients that have severe diarrhoea. Patients should be aware of the possible
occurrence of diarrhoea during treatment and inform their health care provider
if diarrhoea becomes severe. No dosage adjustment is required for patients with
mild hepatic impairment. For patients with moderate to severe hepatic
impairment (Child-Pugh classification B or C), the initial dosage should be
decreased to 24 micrograms (1 capsule once a day with breakfast or supper). If
the initial dose is tolerated and an adequate response has not been obtained
after an appropriate interval, the dose can be increased to full dosing (one
capsule twice daily) with appropriate monitoring of patient response. Patients
may experience dyspnea within an hour of first dose. This symptom generally
resolves within hours, but may recur with repeat dosing. Patients who
experience dyspnea should inform their doctor. Interaction: It is unlikely that
lubiprostone will cause interactions with other medications. Pregnancy and
lactation: AMITIZA should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus. Breast-feeding during use of
AMITIZA is not recommended. Side effects: Most common in clinical studies (in
over 10% of patients) were nausea, diarrhoea and headaches. Other side effects
(in over 1% of patients) were abdominal pain, abdominal distension, flatulence,
vomiting, dizziness, peripheral oedema, fatigue, chest discomfort or pain,
dyspnea, abdominal discomfort, dyspepsia, and dry mouth. Although dyspnea is
not classified as severe, some patients discontinued treatment. Packaging: Soft
capsules in HDPE bottles of 56 (B) with seal and rayon filler. State of
information: May 2013. Sucampo AG, Zug. 

About Sucampo

Sucampo AG, based in Zug, Switzerland, is a wholly-owned subsidiary of Sucampo
Pharmaceuticals, Inc., a global biopharmaceutical company focused on innovative
research, discovery, development and commercialization of proprietary drugs
based on prostones. The therapeutic potential of prostones was first discovered
by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo's Chairman, Chief Executive Officer,
Chief Scientific Officer, and co-founder. Prostones, naturally occurring fatty
acid metabolites that have emerged as promising compounds with unique
physiological activities, can be targeted for the treatment of unmet or
underserved medical needs. For more information, please visit www.sucampo.com. 

Sucampo Forward-Looking Statement

This press release contains 'forward-looking statements' as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks and
uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of pharmaceutical
industry regulation and health care legislation; Sucampo's ability to
accurately predict future market conditions; dependence on the effectiveness of
Sucampo's patents and other protections for innovative products; the risk of
new and changing regulation and health policies in the U.S. and internationally
and the exposure to litigation and/or regulatory actions. No forward-looking
statement can be guaranteed and actual results may differ materially from those
projected. Sucampo undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events, or otherwise. Forward-looking statements in this presentation should be
evaluated together with the many uncertainties that affect Sucampo's business,
particularly those mentioned in the risk factors and cautionary statements in
Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates by
reference. 

Follow us on Twitter (@Sucampo_Pharma). Follow us on Linkedin (Sucampo
Pharmaceuticals). 

Twitter     LinkedIn


         CONTACT: Silvia Taylor
         Senior Vice President, IR, PR,
         and Corporate Communications
         1-240-223-3718
         staylor@sucampo.com
News Source: NASDAQ OMX



13.09.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Sucampo Pharmaceuticals, Inc.
              
               
              Switzerland
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US8649091068
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------
 
Press spacebar to pause and continue. Press esc to stop.